Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
179 participants
OBSERVATIONAL
2022-10-03
2023-02-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
NCT03505515
Pronostic and Predictive Value of EMT in Localized Lung Cancer
NCT03509779
Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.
NCT02785562
A Study in Non-Small Cell Lung Cancer
NCT07174388
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
NCT07215026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 218 participants. Participants who were treated at the participating sites between 01 January 2017 and 30 November 2021 will be included. The data will be collected retrospectively at the specialized centers from the participants medical records and notes. All the participants will be assigned to a single observational cohort:
• Participants With Advanced NSCLC With EGFR Exon-20 Mutations
This multi-center study will be conducted in Canada, France and Hong Kong. The overall duration of the study will be 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants With Advanced NSCLC With EGFR Exon-20 Mutations
Participants diagnosed with advanced NSCLC with EGFR exon 20 insertions (ex20ins) mutations who were treated according to routine clinical practice will be observed retrospectively up to 6 months or until the end of follow-up.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Followed-up at the site between 01 January 2017 and 30 November 2021 for his/her advanced NSCLC, irrespective of their current survival status.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
William Osler Health System
Brampton, Ontario, Canada
Grand River Hospital
Kitchener, Ontario, Canada
Ottawa Hospital Research Institute.
Ottawa, Ontario, Canada
University Health Network Princess Margaret Cancer Research Tower (PMCRT) The MaRS Centre, East Tower
Toronto, Ontario, Canada
Centre Hospitalier de Saint-Quentin
Saint-Quentin, Aisne, France
Hopital Nord - CHU Marseille
Marseille, Bouches-du-Rhone, France
Centre Francois Baclesse
Caen, Calvados, France
Centre Georges Francois Leclerc
Dijon, Cote-d'Or, France
CHU Brest - Hopital Morvan
Brest, Finistere, France
Institut Bergonie
Bordeaux, Gironde, France
Hopital Larrey
Toulouse, Haute Garonne, France
Centre Hospitalier de la Region d'Annecy
Pringy, Haute Savoie, France
Hopital Albert Calmette - CHU Lille
Lille, Nord, France
Institut Curie - site de Paris
Paris, Paris, France
CHU Clermont-Ferrand
Clermont-Ferrand, Puy De Dome, France
Centre Leon Berard
Lyon, Rhone, France
Hospices Civils de Lyon
Lyon, Rhone, France
CHU Strasbourg - Nouvel Hopital Civil
Strasbourg, Rhone, France
Centre Hospitalier Regional de la Reunion
Saint-Pierre, Seine Saint Denis, France
Hospital Center Henri Duffaut
Avignon, Vaculuse, France
Centre Hospitalier Intercommunal de Creteil
Créteil, Val De Marne, France
CHU Poitiers - Hopital la Miletrie
Poitiers, Vienne, France
Hopital de Versailles
Versailles, Yvelines, France
Hopital Tenon
Paris, , France
Pamela Youde Nethersole Eastern Hospital
Hong Kong, , Hong Kong
Prince of Wales Hospital
Hong Kong, , Hong Kong
Princess Margaret Hospital
Hong Kong, , Hong Kong
Queen Elizabeth Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Tuen Mun Hospital
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAK-788-4002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.